World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF OROPHARYNGEAL CANCER USING SIMILAR MOLECULE – LAMBROLIZUMAB

Dr. Syed Ahmed Hussain*, Umaima Batool Osmani, Raheem Unnisa Shaik, Maimuna Fatima, Arshiya Tarannum, Faheem Unnisa and Nazneen

ABSTRACT

Aim: To evaluate the in vitro cytotoxic effects of Lambrolizumab, a PD-1 inhibitor, in comparison to Cetuximab, a
marketed drug, using various cell viability assays. Objective: The primary objective of this study is to determine
the cytotoxic potential of Lambrolizumab on kidney cancer cell lines and assess its viability as a treatment option
for oropharyngeal cancer. Research: Five different assays—MTT, CellTiter-Glo Luminescent, Alamar Blue, SRB,
and LDH Cytotoxicity—were used to assess cell viability, proliferation, and cytotoxicity. Lambrolizumab
demonstrated a significant reduction in cell viability in a dose-dependent manner across all assays, with maximum
efficacy at 10 μM concentration. Compared to Cetuximab, which maintained 100% cell viability, Lambrolizumab
showed enhanced cytotoxic activity, reducing cell viability by up to 42.8% (MTT Assay) and inducing up to 77.2%
cell death (LDH Assay). Conclusion: The findings suggest that Lambrolizumab possesses a strong cytotoxic
profile, making it a promising candidate for further development in oropharyngeal cancer treatment. The study
highlights the potential of immune checkpoint inhibitors like Lambrolizumab to provide better therapeutic
outcomes in resistant cancer types.

[Full Text Article]   [Download Certificate]